$LAHO The Smart Money Is Piling Into Regenerative Medicine
Progressive Approval Could Be a Game Changer for RM Investing in Regenerative Medicine
The Goldman report discusses Samumed, a private RM company. With $300 million in funding,it’s valued at a staggering $12 billion Samumed’s drug platform aims to regenerate various tissues such as bone, cartilage, hair, and skin.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.